Comparative Pharmacology
Head-to-head clinical analysis: BROVANA versus THEOBID JR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BROVANA versus THEOBID JR.
BROVANA vs THEOBID JR.
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BROVANA (arformoterol tartrate) is a long-acting beta2-adrenergic agonist (LABA). It stimulates intracellular adenyl cyclase, increasing cyclic AMP levels, leading to relaxation of bronchial smooth muscle and inhibition of mast cell mediator release.
Inhibits phosphodiesterase, increasing intracellular cAMP; causes bronchodilation, central nervous system stimulation, and positive inotropic/chronotropic effects.
15 mcg (2 mL) by nebulization twice daily, not to exceed 30 mcg/day.
300 mg orally every 12 hours, extended-release tablet. Titrate to serum theophylline concentration of 5-15 mcg/mL.
None Documented
None Documented
Terminal elimination half-life: approximately 26 hours (range 22–30 hours) in healthy adults; prolonged in hepatic impairment (up to 50% increase).
3-8 hours in adults; prolonged in neonates, cirrhosis, heart failure (up to 30 hours). Tobacco smoking induces clearance (half-life 4-5 hours).
Primarily renal (60% unchanged drug); remainder via biliary/fecal (approximately 20%) and metabolic transformation.
Hepatic metabolism (90%), renal excretion of unchanged drug (10%). Metabolites excreted in urine.
Category C
Category C
Bronchodilator
Bronchodilator